CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
research
Efficacy of ω-3 supplementation in patients with psoriasis:a meta-analysis of randomized controlled trials
Authors
Cain Clark
Sadegh Jafarnejad
Mina Nahavandi
Mohsen Taghizadeh
Publication date
1 January 2019
Publisher
'Springer Science and Business Media LLC'
Doi
Cite
Abstract
Several studies have been conducted with the aim of investigating the effect of Omega(�)-3 on different psoriasis indices including Psoriasis Area and Severity Index (PASI) score, erythema, scaling, itching, area involved, and infiltration. Nevertheless, a pooled analysis of trials that evaluated these variables has not been conducted. Therefore, the aim of this meta-analysis was to assess the efficacy of �-3 fatty acids in treating patients with psoriasis. We searched through different electronic, references of retrieved articles, and previous related reviews databases up to November 2018. Both combined and stratified analyzes were conducted. A fixed-effects or random effects model was used to assess the mean effect sizes. An eventual 10 studies involving 560 participants were considered as eligible for inclusion in the present meta-analysis. The meta-analysis indicated a significant reduction in PASI score by � 1.58 (95 confidence interval (CI), � 2.24, � 0.92; P < 0.001) in favor of �-3 polyunsaturated fatty acid (PUFA) group. The random effects model showed a statistically significant beneficial effect of �-3 PUFA supplementation on reducing erythema by � 1.66 unit and reducing scaling (weighted mean difference (WMD), � 0.69; 95 CI, � 1.26, � 0.13; P = 0.02). Significant improvements in erythema, itching, and scale were observed in the trials which used the higher dosage of �-3 supplementation. The results of current meta-analysis study support the use of �-3 PUFA supplementation for the improvement of the evaluated parameters in psoriatic patients. However, well-controlled and randomized studies are needed to confirm the veracity of non-significant and/or equivocal findings. © 2019, International League of Associations for Rheumatology (ILAR)
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
kashan university of medical sciences
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.kaums.ac.ir:3674
Last time updated on 12/06/2019
Coventry University Pure Portal
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pure.atira.dk:publications...
Last time updated on 16/10/2019